Abstract
Twenty‐five patients with metastatic prostate cancer resistant to primary hormone therapy, received high‐dose intravenous diethylstilbestrol diphosphate (Stilphostrol [Miles Pharm], DES‐P) in a Phase II study using established response criteria. Objective response rate was 17%, while 22% of the patients were subjectively improved. Moderate gastrointestinal toxicity was reported in 10 patients (40%). Thromboembolic complications were seen in 2 (8%). The role of high‐dose Stilphostrol in the treatment of hormone‐resistant prostate cancer is limited.
Original language | English (US) |
---|---|
Pages (from-to) | 457-460 |
Number of pages | 4 |
Journal | Cancer |
Volume | 56 |
Issue number | 3 |
DOIs | |
State | Published - Aug 1 1985 |
ASJC Scopus subject areas
- Oncology
- Cancer Research